{"id":21115,"date":"2025-01-09T22:48:50","date_gmt":"2025-01-09T14:48:50","guid":{"rendered":"https:\/\/flcube.com\/?p=21115"},"modified":"2025-01-09T22:48:52","modified_gmt":"2025-01-09T14:48:52","slug":"huidagene-therapeutics-receives-ema-orphan-designation-for-hg004-gene-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21115","title":{"rendered":"HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy"},"content":{"rendered":"\n

Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced a positive opinion from the European Medicines Agency (EMA) for the Committee for Orphan Medicinal Products (COMP) on the orphan designation filing for its HG004. The gene therapy is designed for the treatment of inherited retinal dystrophy caused by dysfunction in the RPE65 gene.<\/p>\n\n\n\n

HG004: Innovative Gene Therapy<\/strong>
HG004 is an innovative gene therapy that offers significant benefits for patients with inherited retinal diseases (RPE65-IRD) caused by RPE65 mutations. It utilizes an optimized retinal pigment epithelium (RPE) tropism viral vector, designed to restore the visual cycle in patients with RPE65 gene mutations. This therapy aims to improve light perception and prevent progressive retinal degeneration that leads to blindness. Previously, the drug was awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) in the US in 2023.<\/p>\n\n\n\n

Inherited Retinal Disease (IRD) Background<\/strong>
Inherited retinal disease (IRD) is a group of rare, genetically defined conditions that lead to progressive vision loss. RPE65 gene mutations are among the most well-known causes of IRD, leading to diseases such as Leber\u2019s congenital amaurosis (LCA), severe early childhood-onset retinal dystrophy (SECORD), early-onset severe retinal dystrophy (EOSRD), and retinitis pigmentosa (RP). These conditions typically onset between birth and five years of age and exhibit several common clinical findings, including night blindness (light staring with profound nyctalopia and nystagmus), progressive loss of visual fields, and loss of central vision. These symptoms significantly impact quality of life and, in many cases, lead to complete blindness. Given the often severe and early visual loss associated with RPE65-IRD, other areas of development, including speech, social skills, and behavior, may also be delayed.<\/p>\n\n\n\n

Significance of the Orphan Designation<\/strong>
The positive opinion from the EMA for the orphan designation of HG004 underscores the potential of this gene therapy to address the significant unmet medical need in treating RPE65-IRD. This designation is expected to facilitate the development and regulatory review process, bringing this innovative treatment option closer to patients in need.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced a positive opinion from the European Medicines…<\/p>\n","protected":false},"author":1,"featured_media":21116,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1619,44,24],"class_list":["post-21115","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-huidagene-therapeutics","tag-ophthalmology","tag-rare-orphan-disease-drugs"],"yoast_head":"\nHuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced a positive opinion from the European Medicines Agency (EMA) for the Committee for Orphan Medicinal Products (COMP) on the orphan designation filing for its HG004. The gene therapy is designed for the treatment of inherited retinal dystrophy caused by dysfunction in the RPE65 gene.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21115\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy\" \/>\n<meta property=\"og:description\" content=\"Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced a positive opinion from the European Medicines Agency (EMA) for the Committee for Orphan Medicinal Products (COMP) on the orphan designation filing for its HG004. The gene therapy is designed for the treatment of inherited retinal dystrophy caused by dysfunction in the RPE65 gene.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21115\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-09T14:48:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-09T14:48:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0920.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"835\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21115#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21115\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy\",\"datePublished\":\"2025-01-09T14:48:50+00:00\",\"dateModified\":\"2025-01-09T14:48:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21115\"},\"wordCount\":344,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21115#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0920.png\",\"keywords\":[\"HuidaGene Therapeutics\",\"Ophthalmology\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21115#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21115\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21115\",\"name\":\"HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21115#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21115#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0920.png\",\"datePublished\":\"2025-01-09T14:48:50+00:00\",\"dateModified\":\"2025-01-09T14:48:52+00:00\",\"description\":\"Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced a positive opinion from the European Medicines Agency (EMA) for the Committee for Orphan Medicinal Products (COMP) on the orphan designation filing for its HG004. The gene therapy is designed for the treatment of inherited retinal dystrophy caused by dysfunction in the RPE65 gene.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21115#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21115\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21115#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0920.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0920.png\",\"width\":1080,\"height\":835,\"caption\":\"HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21115#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy - Insight, China's Pharmaceutical Industry","description":"Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced a positive opinion from the European Medicines Agency (EMA) for the Committee for Orphan Medicinal Products (COMP) on the orphan designation filing for its HG004. The gene therapy is designed for the treatment of inherited retinal dystrophy caused by dysfunction in the RPE65 gene.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21115","og_locale":"en_US","og_type":"article","og_title":"HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy","og_description":"Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced a positive opinion from the European Medicines Agency (EMA) for the Committee for Orphan Medicinal Products (COMP) on the orphan designation filing for its HG004. The gene therapy is designed for the treatment of inherited retinal dystrophy caused by dysfunction in the RPE65 gene.","og_url":"https:\/\/flcube.com\/?p=21115","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-09T14:48:50+00:00","article_modified_time":"2025-01-09T14:48:52+00:00","og_image":[{"width":1080,"height":835,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0920.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21115#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21115"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy","datePublished":"2025-01-09T14:48:50+00:00","dateModified":"2025-01-09T14:48:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21115"},"wordCount":344,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21115#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0920.png","keywords":["HuidaGene Therapeutics","Ophthalmology","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21115#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21115","url":"https:\/\/flcube.com\/?p=21115","name":"HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21115#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21115#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0920.png","datePublished":"2025-01-09T14:48:50+00:00","dateModified":"2025-01-09T14:48:52+00:00","description":"Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced a positive opinion from the European Medicines Agency (EMA) for the Committee for Orphan Medicinal Products (COMP) on the orphan designation filing for its HG004. The gene therapy is designed for the treatment of inherited retinal dystrophy caused by dysfunction in the RPE65 gene.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21115#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21115"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21115#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0920.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0920.png","width":1080,"height":835,"caption":"HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21115#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0920.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21115"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21115\/revisions"}],"predecessor-version":[{"id":21117,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21115\/revisions\/21117"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21116"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}